Siegfried Holding AG ( (SGFEF) ) has released its Q2 earnings. Here is a breakdown of the information Siegfried Holding AG presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Siegfried Holding AG is a global life sciences company that specializes in manufacturing pharmaceutical active pharmaceutical ingredients (APIs) and drug products, with a presence in Switzerland, Germany, Spain, France, Malta, the USA, and China. It is publicly listed on the Swiss Stock Exchange.
In its half-year report for 2025, Siegfried Holding AG reported stable financial performance despite challenging market conditions. The company achieved net sales of CHF 619.5 million, reflecting a slight decrease of 0.1% in Swiss Francs but a 1.6% increase in local currencies. The company also reported a core EBITDA of CHF 133.9 million, maintaining a margin of 21.6%.
Key financial highlights include a core net profit of CHF 65.7 million, a decrease from the previous year due to exchange rate impacts. However, cash flow from operating activities saw a significant increase to CHF 149.6 million. The company also made strategic investments in technology and capacity expansions to support future growth.
Siegfried’s strategic initiatives, including the EVOLVE+ strategy, are on track, focusing on commercial, development, and operational excellence. The company is also committed to sustainability, with validated targets for greenhouse gas reduction.
Looking forward, Siegfried confirms its positive outlook for 2025, expecting mid-single-digit sales growth in local currencies and a core EBITDA margin above 22%, driven by its diversified customer base and efficient operations.